^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
alofanib (RPT835)
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
R-Pharm, Russian Pharmaceutical Technologies
Drug class:
FGFR2 inhibitor
Related drugs:
Phase 1b
Russian Pharmaceutical Technologies
Unknown status
Last update posted :
09/26/2019
Initiation :
05/26/2019
Primary completion :
10/01/2020
Completion :
12/01/2020
FGFR2 • FRS2
|
FGFR2 fusion • FGFR2 amplification • FGFR2 overexpression • FGFR2 expression
|
alofanib (RPT835)
Share
